Real-world study on tebentafusp use in metastatic uveal melanoma in France: interim analysis of the PRIMUM.0 study
Oncology
Données primaires
poster
Auteurs : M. Rodrigues, A. Ducoulombier, E.M. Neidhardt, C. Pages, M. Pracht, M. Laramas, C. Dutriaux, T. Ryckewaert, X. Durando, A. Hervieu, A. Lamoureux, Y. Le Corre, C. Nardin, S. Bastide, K.A. Cage, M. McCully, S. Ruiz, S. Piperno-Neuman
Date de publication : 22 January 2026
Objectives
The objective were to describe clinical outcomes of tebentafusp in patients with metastatic uveal melanoma in a real-world setting.
Conclusion
This retrospective real-world analysis supports the survival benefit and safety profile of tebentafusp observed in the pivotal phase 3 study, affirming its use as a first-line standard of care for HLA-A*02:01-positive patients with mUM.